Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer

EndostarTM Injection Combined With Gemcitabine+Platinum (GP)/Navelbine+Platinum (NP)/Gemcitabine+Xeloda (GX)/Navelbine+Xeloda (NX) in Treatment of Recurrent Metastatic Breast Cancer: A Randomized, Opened and Controlled Clinical Study

Endostatin has been widely applied for the clinical treatment of partial primary and metastatic solid tumors. Endostatin combined with chemotherapy has achieved favorable progression in the treatment of non-small cell lung cancer (NSCLC). However, the research about the efficacy of Endostatin on breast cancer has just started. Breast cancer is a highly-differentiated solid tumor, indicating that it is also an indicator for Endostatin therapy. Additionally, after chemo- and radiotherapy, the primary nidi of patients with advanced breast cancer may also lead to rapid development of tumors in other locations. So Endostatin combined with chemotherapy can also improve the prognosis of patients with recurrent metastatic breast cancer, but there is rare any report at home and abroad. To further explore the above research, this study designed a randomized, opened and controlled clinical study to observe the clinical efficacy of EndostarTM Injection combined with GP/NP/GX/NX in the treatment of recurrent metastatic breast cancer.

Study Overview

• Status: Unknown
• Conditions: Breast Neoplasms
• Intervention / Treatment: Drug: EndostarTM Injection; Drug: Gemcitabine; Drug: Navelbine; Drug: Platinum; Drug: Xeloda Tablets:

Detailed Description

Large amounts of studies have proved that the development of tumor vessels mainly depend on the activation, proliferation, adhesion and maturity of vascular endothelial cells, which may also become the targets of vascular inhibitors. At present, Avastin, an anti-angiogenesis drug, has been marketed in Euopean and American countries, and another 30 kinds of vascular inhibitors are still in trails. Endostatin has been widely applied for the clinical treatment of partial primary and metastatic solid tumors. Endostatin combined with chemotherapy has achieved favorable progression in the treatment of non-small cell lung cancer (NSCLC). However, the research about the efficacy of Endostatin on breast cancer has just started. Breast cancer is a highly-differentiated solid tumor, indicating that it is also an indicator for Endostatin therapy. Additionally, after chemo- and radiotherapy, the primary nidi of patients with advanced breast cancer may also lead to rapid development of tumors in other locations. So Endostatin combined with chemotherapy can also improve the prognosis of patients with recurrent metastatic breast cancer, but there is rare any report at home and abroad. To further explore the above research, this study designed a randomized, opened and controlled clinical study to observe the clinical efficacy of EndostarTM Injection combined with GP/NP/GX/NX in the treatment of recurrent metastatic breast cancer.

• Study Type: Interventional
• Enrollment (Anticipated): 120
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Shun-E Yang, Professor; Phone Number: 0991-7819372 15805197983; Email: 319889719@qq.com
• Study Contact Backup: Name: Wei Liu, Assitant; Phone Number: 7819371 0991-7819372; Email: 319889719@qq.com

Study Locations

• China
  • Xinjiang
    • Urumchi, Xinjiang, China, 830000
      • Recruiting
      • Third Affiliated Hospital of Xinjiang Medical University
      • Contact: Shun-E Yang, Professor; Phone Number: 15805197983; Email: 319889719@qq.com
      • Contact: Xun Li, Assistant; Phone Number: 7819371 0991-7819372; Email: yangshune@medmail.com.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Age: 18～70 years old;
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) score: 0～1 score;
• All patients were diagnosed as recurrent metastatic breast cancer retreatment by histopathology and computed tomography (CT) examination;
• The measurable nidus≥1: Patients whose nidus diameter ≥ 20 mm by normal CT or magnetic resonance image (MRI) scanning, and ≥ 10 mm by spiral CT scanning;
• Patients whose blood routine, hepatorenal function, electrolyte and cardiac function were basically normal without dysfunction of primary organs. White blood cell count (WBC) ≥4.0×109/L, neutrophile granulocyte count ≥1.5×109/L, platelet (PLT) count ≥100×109/L, hemoglobin (HGB) ≥95 g/L, serum bilirubin (BIL) ≤1.5-fold upper limit of normal value, alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤2-fold upper limit of normal value, and serum creatinine (Scr) ≤1.5mg/dl;
• The expected survival time >3 months;
• Patients who could understand this study status and had signed the informed consent forms.

Exclusion Criteria:

• Patients who had history of allergic responses to biological agents;
• Patients who were receiving other anti-tumor therapies;
• Patients without measureable nidus;
• Others, including one of the following conditions: patients with uncontrolled central nervous system (CNS) metastatic nidi, with dysfunction of important organs and severe cardiac diseases (congestive heart failure, uncontrollable arrhythmia, and angina pectoris, valvular heart disease, myocardial infarction and refractory hypertension that required long-term drug administration), with chronic infectious wound and with history of uncontrollable psychosis, and women in pregnant or lactation period.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental group; Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14; EndostarTM Injection: 210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h).	Drug: EndostarTM Injection; 210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h); Other Names: Endostatin; Drug: Gemcitabine; 1.0 m/m2, iv 0.5h, d1, 8; Other Names: GEM; Drug: Navelbine; 40 mg/d, iv, d1, 8; Other Names: NVB; Drug: Platinum; 30 mg/m2, iv 3h, d1-3; Other Names: DDP; Drug: Xeloda Tablets: 2 000 mg/m2, po, d1-14; Other Names: ECX
Active Comparator: Control group; Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14.	Drug: Gemcitabine; 1.0 m/m2, iv 0.5h, d1, 8; Other Names: GEM; Drug: Navelbine; 40 mg/d, iv, d1, 8; Other Names: NVB; Drug: Platinum; 30 mg/m2, iv 3h, d1-3; Other Names: DDP; Drug: Xeloda Tablets: 2 000 mg/m2, po, d1-14; Other Names: ECX

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
response rate	response rate that defined as the total ratio of study subjects with complete response, complete response unconfirmed and partial response after treatment. ORR=(CR+ CRu+ PR)cases/total cases×100%.	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
clinical benefit rate	clinical benefit rate that defined as the total ratio of study subjects with complete response，partial response and stable disease more than 24 months after treatment.	2 years
progression-free survival	Progression-free survival (PFS) defined as the ratio of study subjects who had disease progression or died from the start of randomization.	2 years
median survival time	median survival time defined as the corresponding survival time when the cumulative survival rate is 50%.	2 years
overall survival	overall survival rate (OS) that defined as the ratio of study subjects who survived after randomization	2 years
adverse responses	adverse responses that defined as the evaluated by rates of all adverse reactions caused by Recombinant Human Endostatin and the changes of all indexes before and after treatment	2 years

Collaborators and Investigators

• Sponsor: Xinjiang Medical University
• Investigators: Principal Investigator: Shun-E Yang, Professor, Third Affiliated Hospital of Xinjiang Medical University

Study record dates

Study Major Dates

• Study Start: October 1, 2015
• Primary Completion (Anticipated): May 1, 2018
• Study Completion (Anticipated): July 1, 2018

Study Registration Dates

• First Submitted: July 1, 2015
• First Submitted That Met QC Criteria: July 1, 2015
• First Posted (Estimate): July 3, 2015

Study Record Updates

• Last Update Posted (Actual): July 17, 2017
• Last Update Submitted That Met QC Criteria: July 12, 2017
• Last Verified: July 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Gemcitabine; Vinorelbine; Endostatins
• Other Study ID Numbers: XinjiangMU001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No